Research by Yang J et al. found that compared to mpMRI and clinical presentation, [68Ga]Ga-PSMA-11 PET/CT demonstrated higher diagnostic efficacy for PI-RADS 3 score patients and had an advantage over the european randomized study of screening for prostate cancer risk calculator 3 (ERSPC-RC3) and prostate cancer prevention trial risk calculator (PCPT-RC) models23. This evidence concerns the gene FOLH1 and Familial prostate cancer.